Skip to main content
Article
Vitamin D3 Supplemental Treatment for Mania in Youth with Bipolar Spectrum Disorders
Psychiatry Publications and Presentations
  • Elif M. Sikoglu, University of Massachusetts Medical School
  • Ana A. Liso Navarro, University of Massachusetts Medical School
  • Debra Starr, University of Massachusetts Medical School
  • Yael Dvir, University of Massachusetts Medical School
  • Benjamin U. Nwosu, University of Massachusetts Medical School
  • Suzanne M. Czerniak, University of Massachusetts Medical School
  • Ryan C. Rogan, University of Massachusetts Medical School
  • Martha C. Castro, University of Massachusetts Medical School
  • Richard A.E. Edden, Johns Hopkins University School of Medicine
  • Jean A. Frazier, University of Massachusetts Medical School
  • Constance M. Moore, University of Massachusetts Medical School
UMMS Affiliation
Center for Comparative NeuroImaging; Child and Adolescent NeuroDevelopment Initiative; Department of Psychiatry; Department of Pediatrics, Division of Endocrinology
Date
6-1-2015
Document Type
Article
Abstract

OBJECTIVE: We aimed to determine the effect of an open-label 8 week Vitamin D3 supplementation on manic symptoms, anterior cingulate cortex (ACC) glutamate, and γ-aminobutyric acid (GABA) in youth exhibiting symptoms of mania; that is, patients with bipolar spectrum disorders (BSD). We hypothesized that an 8 week Vitamin D3 supplementation would improve symptoms of mania, decrease ACC glutamate, and increase ACC GABA in BSD patients. Single time point metabolite levels were also evaluated in typically developing children (TD).

METHODS: The BSD group included patients not only diagnosed with BD but also those exhibiting bipolar symptomology, including BD not otherwise specified (BD-NOS) and subthreshold mood ratings (Young Mania Rating Scale [YMRS] ≥8 and Clinical Global Impressions - Severity [CGI-S] ≥3). Inclusion criteria were: male or female participants, 6-17 years old. Sixteen youth with BSD exhibiting manic symptoms and 19 TD were included. BSD patients were asked to a take daily dose (2000 IU) of Vitamin D3 (for 8 weeks) as a supplement. Neuroimaging data were acquired in both groups at baseline, and also for the BSD group at the end of 8 week Vitamin D3 supplementation.

RESULTS: Baseline ACC GABA/creatine (Cr) was lower in BSD than in TD (F[1,31]=8.91, p=0.007). Following an 8 week Vitamin D3 supplementation, in BSD patients, there was a significant decrease in YMRS scores (t=-3.66, p=0.002, df=15) and Children's Depression Rating Scale (CDRS) scores (t=-2.93, p=0.01, df=15); and a significant increase in ACC GABA (t=3.18, p=0.007, df=14).

CONCLUSIONS: Following an 8 week open label trial with Vitamin D3, BSD patients exhibited improvement in their mood symptoms in conjunction with their brain neurochemistry.

Comments

Citation: Sikoglu EM, Navarro AA, Starr D, Dvir Y, Nwosu BU, Czerniak SM, Rogan RC, Castro MC, Edden RA, Frazier JA, Moore CM. Vitamin D3 Supplemental Treatment for Mania in Youth with Bipolar Spectrum Disorders. J Child Adolesc Psychopharmacol. 2015 Jun;25(5):415-24. doi: 10.1089/cap.2014.0110. PubMed PMID: 26091195; PubMed Central PMCID: PMC4491165. Link to article on publisher's site

Related Resources
Link to article in PubMed
PubMed ID
26091195
Citation Information
Elif M. Sikoglu, Ana A. Liso Navarro, Debra Starr, Yael Dvir, et al.. "Vitamin D3 Supplemental Treatment for Mania in Youth with Bipolar Spectrum Disorders" Vol. 25 Iss. 5 (2015) ISSN: 1557-8992
Available at: http://works.bepress.com/benjamin_nwosu/36/